These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 10686311)
21. Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation. Land W Transplant Proc; 1999 Dec; 31(8A):27S-32S. PubMed ID: 10616558 [No Abstract] [Full Text] [Related]
22. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Shapiro R; Jordan ML; Scantlebury VP; Vivas C; Marsh JW; McCauley J; Johnston J; Randhawa P; Irish W; Gritsch HA; Naraghi R; Hakala TR; Fung JJ; Starzl TE Transplant Proc; 1999; 31(1-2):1134. PubMed ID: 10083507 [No Abstract] [Full Text] [Related]
23. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Meier-Kriesche HU; Friedman G; Jacobs M; Mulgaonkar S; Vaghela M; Kaplan B Transplantation; 1999 Nov; 68(10):1496-502. PubMed ID: 10589946 [TBL] [Abstract][Full Text] [Related]
24. Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Keunecke C; Rothenpieler U; Zanker B; Schneeberger H; Illner WD; Theodorakis J; Stangl M; Land W Transplant Proc; 2000 Feb; 32(1A Suppl):6S-8S. PubMed ID: 10686310 [No Abstract] [Full Text] [Related]
25. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis. Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570 [No Abstract] [Full Text] [Related]
26. Mycophenolate mofetil (Cellcept) in renal transplantation: the European experience. The European Mycophenolate Mofetil Co-operative Study Group. Carl S; Wiesel M Transplant Proc; 1997 Nov; 29(7):2932-5. PubMed ID: 9365619 [No Abstract] [Full Text] [Related]
27. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910 [TBL] [Abstract][Full Text] [Related]
28. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation. Baker GM; Martin JE; Jang R; Schroeder TJ; Armitstead JA; Myre S; First MR Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304 [No Abstract] [Full Text] [Related]
30. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Birkeland SA Transplantation; 2001 Apr; 71(8):1089-90. PubMed ID: 11374407 [TBL] [Abstract][Full Text] [Related]
31. A single center experience with mycophenolate mofetil in the prevention of renal allograft rejection. Behrend M; Lück R; Köthe P; Pichlmayr R Transplant Proc; 1996 Dec; 28(6):3110-1. PubMed ID: 8962205 [No Abstract] [Full Text] [Related]
32. Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Miller J Transplant Proc; 1999; 31(1-2):276-7. PubMed ID: 10083106 [No Abstract] [Full Text] [Related]
33. Mycophenolate mofetil in renal graft recipients with increased immune risk of graft loss. Boratyńska M; Magott M; Klinger M; Smolska D; Rychlewska B; Myszka K; Szepietowski T; Szyber P; Patrzalek D Transplant Proc; 2002 Mar; 34(2):553-5. PubMed ID: 12009621 [No Abstract] [Full Text] [Related]
34. Treatment with mycophenolate mofetil in kidney transplant patients with organs from donors aged over 60 years: one-year monitoring results. Agraz I; Guirado L; Andrade M; Olaya M; Vila A; Solá R Transplant Proc; 1999 Sep; 31(6):2272-4. PubMed ID: 10500573 [No Abstract] [Full Text] [Related]
35. Improvement in long-term graft survival in cadaveric renal transplant recipients treated with mycophenolate mofetil. Hazzan M; Provot F; Glowacki F; Copin MC; Roumilhac D; Labalette M; Pruvot FR; Noel C Transpl Int; 2004 Oct; 17(9):525-30. PubMed ID: 15338120 [TBL] [Abstract][Full Text] [Related]
37. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients. Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338 [TBL] [Abstract][Full Text] [Related]
38. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912 [TBL] [Abstract][Full Text] [Related]
39. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients. Kandus A; Grego K; Bren AF Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003 [TBL] [Abstract][Full Text] [Related]